Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1
Abstract Background Due to the high drug resistance of hepatocellular carcinoma (HCC), sorafenib has limited efficacy in the treatment of advanced HCC. Cancer-associated fibroblasts (CAFs) play an important regulatory role in the induction of chemoresistance. This study aimed to clarify the mechanis...
Saved in:
| Main Authors: | Jiali Zhao, En Lin, Zirui Bai, Yingbin Jia, Bo Wang, Yihua Dai, Wenfeng Zhuo, Guifang Zeng, Xialei Liu, Chaonong Cai, Peiping Li, Baojia Zou, Jian Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11613-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAT and CXCL8 are crucial cofactors for the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma, the immune infiltration and prognosis of hepatocellular carcinoma
by: Liang Yang, et al.
Published: (2025-03-01) -
Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
by: Wenjun Meng, et al.
Published: (2024-12-01) -
Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2024-12-01) -
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
by: Young Eun Chon, et al.
Published: (2025-01-01) -
Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma
by: Eiji Higaki, et al.
Published: (2020-06-01)